Regulus Therapeutics (RGLS) Tops Q1 EPS by 10c
Tweet
Share
E-mail
Get Alerts RGLS Hot Sheet
Join SI Premium – FREE
Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.15), $0.10 better than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trex (TREX) Reiterated at Hold by Benchmark as Partnership Agreement Announced
- Goldman Sachs expects June CPI to show core inflation below consensus
- Needham sees Paramount Skydance-Warner Bros deal closing despite suit
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
